Chiesi Farmaceutici S.p.a.

Genentech, Inc.

Merck Serono S. A.

F. Hoffmann-la Roche Ag

Charles Baker-Glenn

Elisabetta Armani

Gabriele Amari

Zachary Kevin Sweeney

Anthony A Estrada

Bryan K Chan

Mark Stewart Chambers

Wesley Peter Blackaby

Huifen Chen

Mauro Riccaboni

Daniel J Burdick

Naimisha Trivedi

Daniel Jon Burdick

Carmelida Capaldi

Daniel Shore

Hervé Van De Poël

Anna Quattropani

Guiling Zhao

Shumei Wang

Chris Knight

Ben Whittaker

Anthony Estrada

Mark Chambers

Ian Linney

Agnes Bombrun

Andrea Rizzi

Janet L Gunzner-Toste

Zachary Sweeney

Herve Van De Poeol

Herve Van De Poel

Joseph P Lyssikatos

Matthias Schwarz

Timothy Heffron

Jerome Dorbais

Jerome Gonzalez

Eleonora Ghidini

Jennafer Dotson

Renato De Fanti

Christophe Cleva

Delphine Marin

Eric Sebille

Agnès Bombrun

Craig Rouse

Janet Gunzner-Tate

Herve′ Van De Poel

Janet Gunzner-Toste

Joseph Lyssikatos

Daniel John Burdick

David Shore

Compounds of formula (I), defined herein, are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract.

Aminoester derivatives

The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. 

3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors

The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. 

3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)- 2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors

Compounds of formula (I) are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

Compounds of formula (I) defined herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for treating diseases of the respiratory tract.

Compounds of formula (I) defined herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract.

Carbamate derivatives

Bicyclic pyrazole LRRK2 small molecule inhibitors

Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

Pyrazole aminopyrimidine derivatives as LRRK2 modulators

Compounds of formula (I) described herein are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

Compounds

Compounds of formula (I) described herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

Inhibitors of PDE4 enzyme and antagonists of muscarinic M3 receptor

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein m, n. X, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

Aminopyrimidine derivatives as LRRK2 modulators

Compounds having a benzhydryl structure represented by formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for treating diseases of the respiratory tract.

Benzhydryl derivatives

Compounds of formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

Heteroaryl derivatives

Growing community of inventors

Essex, United Kingdom

Charles Baker-Glenn